The board of directors of Pfizer Inc. today declared a 36-cent
second-quarter 2019 dividend on the company’s common stock, payable June
7, 2019 to shareholders of record at the close of business on May 10,
2019. The second-quarter 2019 cash dividend will be the 322nd
consecutive quarterly dividend paid by Pfizer.
"In 2018, we estimate that we reached more than 784 million people with
our products,” stated Albert Bourla, Pfizer Chief Executive Officer.
"Our vaccines protected more than 65 million babies and elderly patients
from disease; more than 48 million cardiovascular patients took our
medicines to reduce their risk of heart attack or stroke; and more than
1.2 million people were treated with our cancer treatments. Our
unwavering focus on patient impact by discovering breakthroughs
that change patients’ lives will continue to be fundamental to
our growth strategy for the future.”
He continued, "Our ability to have a demonstrable impact on patients
drives our financial performance and creates shareholder value. In 2018,
we returned $20.2 billion to shareholders through dividends and share
repurchases. We will continue to pursue initiatives in 2019 that create
the most value for our shareholders by serving our patients with
advancements in scientific innovation, our late-stage pipeline and our
Preliminary results from the Annual Meeting of Shareholders held today
indicate that the company’s 11 director nominees were re-elected to
one-year terms and that shareholders ratified the selection of KPMG LLP
as Pfizer’s independent registered public accounting firm for the 2019
fiscal year. In addition, shareholders supported the board-sponsored
proposals to approve, on an advisory basis, the compensation of the
company’s named executive officers and approved the Pfizer Inc. 2019
Stock Plan which will replace and supersede the 2014 Stock Plan and
support the company’s efforts to attract, retain and motivate employees.
In other voting, the shareholder proposals were not approved.
The final results are subject to verification by the independent
inspectors of election. The final results will be reported on a Current
Report on Form 8-K to be filed by Pfizer with the U.S. Securities and
Exchange Commission in the next few days.
Pfizer Inc.: Working together for a healthier world®
At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world's
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world's
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all who
rely on us. We routinely post information that may be important to
investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com and
follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube,
and like us on Facebook at Facebook.com/Pfizer.
DISCLOSURE NOTICE: The information contained in this release is as of
April 25, 2019. The Company assumes no obligation to update
forward-looking statements contained in this release as a result of new
information or future events or developments.
This release contains forward-looking information about the Company’s
growth strategy and actions to enhance shareholder value, including
their potential benefits, that involves substantial risks and
uncertainties that could cause actual results to differ materially from
those expressed or implied by such statements. Risks and uncertainties
include, among other things, the uncertainties inherent in research and
development; the uncertainties inherent in business and financial
planning, including, without limitation, risks related to Pfizer’s
business and prospects, adverse developments in Pfizer’s markets, or
adverse developments in the U.S. or global capital markets,
credit markets, regulatory environment or economies generally; and
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2018 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned "Risk Factors” and "Forward-Looking
Information and Factors That May Affect Future Results,” as well as in
its subsequent reports on Form 8-K, all of which are filed with the U.S.
Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190425005635/en/